GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (FRA:LWB) » Definitions » Net Margin %

Mesoblast (FRA:LWB) Net Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Mesoblast's Net Income for the three months ended in Jun. 2024 was €0.00 Mil. Mesoblast's Revenue for the three months ended in Jun. 2024 was €0.00 Mil. Therefore, Mesoblast's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Mesoblast's Net Margin % or its related term are showing as below:


FRA:LWB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

Mesoblast Net Margin % Historical Data

The historical data trend for Mesoblast's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Net Margin % Chart

Mesoblast Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -246.54 -1,329.22 -894.55 -1,091.78 -1,490.26

Mesoblast Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mesoblast's Net Margin %

For the Biotechnology subindustry, Mesoblast's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mesoblast's Net Margin % falls into.



Mesoblast Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mesoblast's Net Margin for the fiscal year that ended in Jun. 2024 is calculated as

Net Margin=Net Income (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-81.711/5.483
=-1,490.26 %

Mesoblast's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast  (FRA:LWB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Mesoblast Net Margin % Related Terms

Thank you for viewing the detailed overview of Mesoblast's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast Business Description

Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Headlines

No Headlines